Biosimilar momentum Napp has launched biosimilars in the UK, including PelMeg, and is part of a global network focused on biosimilars and innovative therapies. This presents opportunities to cross-sell biosimilar portfolios, negotiate partnerships, and expand tender access in healthcare systems seeking cost-effective biologics.

Global reach Active distribution across 120+ countries with emphasis on Europe, Africa, Asia Pacific, Canada, Latin America, and the Middle East suggests a readiness to engage distributors and GPOs in multiple regions, enabling scalable market-entry strategies and regional co-marketing opportunities.

Clinical focus Portfolio areas include Pain Management, CNS, Oncology, Ophthalmology, Diabetes, Transplantation immunity and Infectious diseases. This breadth indicates potential for cross-division deals, patient access programs, and partnerships to expand hospital and clinic adoption of niche therapies.

Recognition and culture Awards for Great Place to Work and strong employer engagement signals a stable partner for long-term collaborations, with potential for joint patient access programs, training partnerships, and co-promotional initiatives in the UK and EU markets.

Tech-enabled ops Utilizes cloud and data tools (Tableau, AWS, Microsoft 365, DocuSign, WordPress) which can facilitate digital sales enablement, contract automation, and analytics-driven targeting for healthcare buyers, enabling faster deal cycles and improved customer experiences.